U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07659002) titled 'Polyvalent Antivenom (Premium-PANAF) for Snakebite Envenoming in Ethiopia' on May 21.
Brief Summary: Snakebite Envenomation is recognised as a Neglected Tropical Diseases with high lethality in Sub-Saharan Africa. The current syndromic treatment approach is also fraught by supply pipeline constraints and need for cold-chain, thus negatively impacting outcomes in resource limited settings.
Despite the lack of clinical outcome data from studies in humans, after a comprehensive risk-benefit assessment, the World Health Organisation (WHO), in May 2023, recommended the use of Premium-PANAF polyvalent snake antivenom that is lyophilised,...